aafp colon cancer screening 2021 :: Article CreatorColon Cancer News
Oct. 17, 2022 — Researchers have identified a new gene that is essential to colon cancer growth and found that inflammation in the external environment around the tumor can contribute to the growth of tumor ...
Sep. 8, 2022 — Physical activity may be associated with improved outcomes for patients undergoing postoperative treatment for Stage III colon cancer, a new study ...
Aug. 10, 2022 — In a new study, researchers define how the circadian clock influences cell growth, metabolism and tumor progression. Their research also reveals how disruption of the circadian clock impacts genome ...
Aug. 4, 2022 — Researchers have combined optical coherence tomography (OCT) and machine learning to develop a colorectal cancer imaging tool that may one day improve the traditional endoscopy currently used by ...
Aug. 2, 2022 — Colorectal tumors are a common adverse effect of chronic inflammation of the intestine. In a new study, researchers demonstrate that mice models with dendritic cell immunoreceptor (DCIR) protein ...
July 25, 2022 — Researchers designed a silicon-based agent that successfully generated hydrogen continuously in the mouse gastrointestinal tract in an ulcerative colitis (UC) model. The hydrogen served as an ...
July 22, 2022 — Colorectal tumors are swarming with white blood cells, but whether these cells help or hinder the cancer is hotly debated. While some studies have shown that white blood cells heroically restrict ...
July 14, 2022 — Data suggest that Clostridioides difficile, or C. Diff, a bacterial species well known for causing serious diarrheal infections, may also drive colorectal ...
June 27, 2022 — New research builds the case that a Western-style diet -- rich in red and processed meat, sugar and refined grains/carbohydrates -- is tied to higher risk of colorectal cancer through the intestinal ...
June 23, 2022 — New research in mice has paved the way for a Phase I clinical trial and has the potential to transform vaccines against HIV and ...
June 21, 2022 — A new combination therapy to combat cancer could one day consist of a plant virus and an antibody that activates the immune system's 'natural killer' cells, shows a new study. In mouse ...
June 14, 2022 — Researchers have discovered a possible new approach in treating solid tumors through the creation of a novel ...
June 4, 2022 — A multi-institutional, international study found that testing for ctDNA after surgery and directing chemotherapy to ctDNA-positive patients reduced the use of chemotherapy overall without ...
May 5, 2022 — A new study reports a 50 to 60 percent lower risk of colorectal cancer (CRC) among women who started endoscopy screening at age 45 compared to those who had not undergone screening at ...
Apr. 27, 2022 — Beta-hydroxybutyrate, an alternative-energy molecule produced by the body in response to starvation or low-carb diets, strongly suppresses the growth of colorectal tumors in lab experiments, ...
Apr. 18, 2022 — Artificial intelligence reduced by twofold the rate at which precancerous polyps were missed in colorectal cancer screening, reported a team of international ...
Apr. 14, 2022 — In patients with familial adenomatous polyposis, a genetic disease predisposing to colon cancer, mutations of the APC gene induce the formation of intestinal polyps, but also reduce immune system ...
Apr. 5, 2022 — Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...
Mar. 31, 2022 — Scientists identify a pathway of immune cell inhibition that may provide the basis for novel approaches to immunotherapy of colon cancer. Their results also highlight important roles of the ...
Mar. 22, 2022 — Accelerated glucose uptake and metabolism, known as the Warburg effect, is a feature of a small group of non-dividing cells within a colon cancer tumor. Intestinal cancer cells rely on Warburg ...
Monday, October 17, 2022
Thursday, September 8, 2022
Wednesday, August 10, 2022
Thursday, August 4, 2022
Tuesday, August 2, 2022
Monday, July 25, 2022
Friday, July 22, 2022
Thursday, July 14, 2022
Monday, June 27, 2022
Thursday, June 23, 2022
Tuesday, June 21, 2022
Tuesday, June 14, 2022
Saturday, June 4, 2022
Thursday, May 5, 2022
Wednesday, April 27, 2022
Monday, April 18, 2022
Thursday, April 14, 2022
Tuesday, April 5, 2022
Thursday, March 31, 2022
Tuesday, March 22, 2022
Thursday, March 10, 2022
Friday, March 4, 2022
Thursday, March 3, 2022
Monday, February 28, 2022
Tuesday, February 15, 2022
Friday, February 11, 2022
Wednesday, January 19, 2022
Wednesday, January 12, 2022
Friday, January 7, 2022
Tuesday, December 14, 2021
Monday, December 13, 2021
Thursday, December 2, 2021
Thursday, November 18, 2021
Thursday, November 4, 2021
Wednesday, October 20, 2021
Thursday, October 14, 2021
Wednesday, October 6, 2021
Tuesday, September 28, 2021
Thursday, September 23, 2021
Friday, September 17, 2021
Monday, September 13, 2021
Wednesday, September 1, 2021
Thursday, August 19, 2021
Tuesday, August 17, 2021
Thursday, August 12, 2021
Thursday, June 24, 2021
Monday, June 14, 2021
Tuesday, May 18, 2021
Saturday, May 15, 2021
Thursday, April 22, 2021
Monday, February 22, 2021
Wednesday, February 17, 2021
Tuesday, February 2, 2021
Monday, February 1, 2021
Wednesday, January 27, 2021
Thursday, January 21, 2021
Tuesday, December 1, 2020
Wednesday, November 4, 2020
Tuesday, November 3, 2020
CRC Screening Uptake No Better With Use Of Fecal Immunochemical Testing In At-risk Individuals
For first-degree relatives of patients with nonsyndromic colorectal cancer (CRC), fecal immunochemical testing (FIT) screening does not improve screening uptake compared with colonoscopy screening, according to a study published online Oct. 24 in PLOS Medicine.
Natalia González-López, from the Hospital Universitario de Canarias in Tenerife, Spain, and colleagues examined whether uptake of FIT screening is superior to uptake of colonoscopy screening in a population of FDRs of patients with CRC.
The open-label, parallel-group trial was conducted in 12 centers between February 2016 and December 2021. Eligible participants were FDRs of index cases younger than 60 years or having two or more index cases or a sibling with CRC, regardless of age at diagnosis; 1,760 FDRs of 460 index cases were assessed for inclusion: 870 were assigned to undergo one-time colonoscopy or FIT (431 and 439, respectively).
The researchers found that of those assigned to undergo colonoscopy or FIT, 44.0% attended the appointment and signed informed consent: 34.1 and 35.9% underwent colonoscopy-based screening and FIT-based screening, respectively (odds ratio, 1.08; 95% confidence interval, 0.82 to 1.44; P = 0.564).
Compared with the FIT group, the colonoscopy group had a significantly higher detection rate of advanced colorectal neoplasia (odds ratio, 3.64; 95% confidence interval, 1.55 to 8.53; P = 0.003). Throughout follow-up, there was no change noted in study outcomes.
"In the setting of an opportunistic screening, annual FIT does not increase the screening uptake compared to colonoscopy screening in FDR at high risk of developing CRC, resulting in a significantly lower detection rate of advanced colorectal neoplasia," the authors write.
More information: Natalia González-López et al, Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study), PLOS Medicine (2023). DOI: 10.1371/journal.Pmed.1004298
Copyright © 2023 HealthDay. All rights reserved.
Citation: CRC screening uptake no better with use of fecal immunochemical testing in at-risk individuals (2023, October 25) retrieved 31 October 2023 from https://medicalxpress.Com/news/2023-10-crc-screening-uptake-fecal-immunochemical.Html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Prostate Vs. Colon Cancer: Your Questions Answered
Prostate and colon cancer share some risk factors, but they're distinct conditions. They affect different organs and have different symptoms. The screening process and guidelines for both also differ.
Prostate cancer happens when cancerous cells grow in your prostate gland. This gland is connected to the urethra in people assigned male at birth, and it stores and carries sperm during ejaculation.
Colon cancer happens when cancerous cells grow in your large intestine. Your colon is part of your gastrointestinal (GI) tract. Your GI tract does not include your prostate.
Prostate and colon cancer are two of the most common types of cancer in the United States. Read on to learn how common each type is, what early signs and symptoms to watch out for, and how doctors diagnose and treat them.
According to the National Cancer Institute, prostate cancer is the second most commonly diagnosed form of cancer in the United States. Yet death from prostate cancer isn't as common as it is with several other cancers.
Colorectal cancer, which includes colon cancer, is the fourth most commonly diagnosed form of cancer. But it's the second most common cause of death from cancer.
The American Cancer Society (ACS) estimates there will be about 288,300 new prostate cancer diagnoses in 2023, compared with 106,970 new colon cancer diagnoses. Still, the ACS predicts that colorectal cancer will be responsible for about 18,000 more deaths than prostate cancer.
Plus, a 2020 research review found that cancer screening was much less common for African Americans, Asian Americans, Latinx Americans, and American Indians. This means that actual rates of prostate and colon cancer may be inaccurate due to the lack of access to adequate medical resources in many of these communities.
Age is a risk factor for both prostate and colon cancer. The average age of diagnosis for prostate cancer is 66 years, while it ranges from 68–72 years for colon cancer. However, rates of colorectal cancer among adults ages 50 and younger have been increasing in recent years, according to 2019 research.
A family history of either condition also increases your risk of that cancer.
A personal history of GI disorders like inflammatory bowel disease can also increase your risk of colon cancer.
Data from the Office of Minority Health suggests that the risk of both prostate and colorectal cancer is higher in Black people in the United States. This stems partly from disparities in healthcare for Black people, such as limited access to care and a lower quality of care.
The early signs and symptoms of prostate and colon cancer usually differ by location in the body. People with prostate cancer often don't experience any symptoms until later stages.
The most widely recognized symptoms of prostate cancer are changes in your urinary habits and function. Other symptoms include:
Colon cancer causes changes in your bowel habits and can cause pain in your abdomen. Other symptoms of colon cancer include:
The ACS recommends you undergo screening for prostate cancer starting at age 50, with recommendations for earlier screenings if you're Black or have a close relative with prostate cancer.
Screening tests for prostate cancer include:
The U.S. Preventive Services Task Force recommends starting colon cancer screening at age 45. If you have a family history or other risk factors, talk with your healthcare team about what age you should start receiving screening to help ensure cancer is caught early.
Screening tests for colon cancer include:
fecal testing to look for blood or other substances in your blood that can indicate colon cancer liver function tests or blood tests to rule out other conditions that can cause similar symptoms sigmoidoscopy or colonoscopy to look inside your colon for cancer and remove tissue for biopsy X-rays and CT scans to get detailed images of your colon and the surrounding areas Prostate cancer tends to grow more slowly than colon cancer, so treatment may be less invasive and mainly consist of active surveillance to ensure it doesn't grow to an unmanageable level.
If cancerous cells have taken over your prostate, you may need a simple or radical prostatectomy to remove your prostate gland. If the cancer spreads further, you may also need:
Colon cancer often grows quickly and can spread beyond your colon. Colon cancer also tends to disrupt your body's ability to digest food and pass waste, which can be dangerous to your overall health.
Active surveillance may be necessary at the earliest stages of colon cancer. As cancerous cells spread, some treatment options for colon cancer might include:
Even after successful treatment, some people with prostate or colon cancer can develop a second, unrelated cancer.
A 2017 Korean study found that the risk of prostate cancer in people over age 55 was higher if they previously had colorectal cancer.
Similarly, a 2016 Canadian study found that the risk of colon cancer may be higher in people who previously underwent radiation for prostate cancer.
However, the ACS notes that the following second cancers are more common for prostate cancer and for colon cancer:
Prostate cancer affects the prostate gland in people assigned male at birth. Colon cancer affects your large intestine, which helps you digest food and remove waste.
The symptoms, diagnostic tests, and treatments for each type of cancer are different and require different specialists. Talk with a doctor if you're concerned about early signs of these cancers.
Comments
Post a Comment